Toward the future of psychiatric diagnosis: the seven pillars of RDoC

BMC Medicine

Thomas R Insel¹  Bruce N Cuthbert¹ 

[1] Express/parcel delivery, Rockville, MD 20852, USA

关键词: Research domain criteria;    RDoC;    Psychopathology;    Psychiatric diagnosis;    ICD;    Diagnosis, DSM;   

Others  :  857034
DOI  :  10.1186/1741-7015-11-126

 received in 2012-10-23, accepted in 2013-03-13,  发布年份 2013

【 摘 要 】

Background

Current diagnostic systems for mental disorders rely upon presenting signs and symptoms, with the result that current definitions do not adequately reflect relevant neurobiological and behavioral systems - impeding not only research on etiology and pathophysiology but also the development of new treatments.

Discussion

The National Institute of Mental Health began the Research Domain Criteria (RDoC) project in 2009 to develop a research classification system for mental disorders based upon dimensions of neurobiology and observable behavior. RDoC supports research to explicate fundamental biobehavioral dimensions that cut across current heterogeneous disorder categories. We summarize the rationale, status and long-term goals of RDoC, outline challenges in developing a research classification system (such as construct validity and a suitable process for updating the framework) and discuss seven distinct differences in conception and emphasis from current psychiatric nosologies.

Summary

Future diagnostic systems cannot reflect ongoing advances in genetics, neuroscience and cognitive science until a literature organized around these disciplines is available to inform the revision efforts. The goal of the RDoC project is to provide a framework for research to transform the approach to the nosology of mental disorders.

【 授权许可】

   
2013 Cuthbert and Insel; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Wing L, Gould J, Gillberg C: Autism spectrum disorders in the DSM-V: better or worse than the DSM-IV? Res Dev Disabil 2011, 32:768-773.
• [2]Friedman RA: Grief, depression, and the DSM-5. N Engl J Med 2012, 366:1855-1857.
• [3]Skodol AE: Personality disorders in DSM-5. Annual Rev of Clinical Psychology 2012, 8:317-344.
• [4]Clarkin JF, Huprich SK: Do DSM-5 personality disorder proposals meet criteria for clinical utility? J Pers Disorders 2011, 25:192-205.
• [5]Phillips J, Frances A, Cerullo MA, Chardavoyne J, Decker HS, First MB, Ghaemi N, Greenberg G, Hinderliter AC, Kinghorn WA, LoBello SG, Martin EB, Mishara AL, Paris J, Pierre JM, Pies RW, Pincus HA, Porter D, Pouncey C, Schwartz MA, Szasz T, Wakefield JC, Waterman GS, Whooley O, Zachar P: The six most essential questions in psychiatric diagnosis: a pluralogue part 1: conceptual and definitional issues in psychiatric diagnosis. Philos Ethics Humanit Med 2012, 7:3. BioMed Central Full Text
• [6]Phillips J, Frances A, Cerullo MA, Chardavoyne J, Decker H, First MD, Ghaemi N, Greenberg G, Hinderliter AC, Kinghorn WA, LoBello SG, Martin EB, Mishara AL, Paris J, Pierre JM, Pies RW, Pincus HA, Porter D, Pouncey C, Schwartz MA, Szasz T, Wakefield JC, Waterman GS, Whooley O, Zachar P: The six most essential questions in psychiatric diagnosis: a pluralogue part 3: issues of utility and alternative approaches in psychiatric diagnosis. Philos Ethics Humanit Med 2012, 7:9. BioMed Central Full Text
• [7]Varga S: Defining mental disorder: exploring the ‘natural function’ approach. Philos Ethics Humanit Med 2011, 6:1. BioMed Central Full Text
• [8]Nesse RM, Stein DJ: Towards a genuinely medical model for psychiatry. BMC Med 2012, 10:5. BioMed Central Full Text
• [9]Dictionary.com [http://www.dictionary.com webcite]
• [10]Sensky T, Turkington D, Kingdon D, Scott JL, Scott J, Siddle R, O’Carroll M, Barnes RE: A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch Gen Psychiatry 2000, 57:165-172.
• [11]National Heart, Lung, and Blood Institute: NHLBI Fact Book, Fiscal Year. Bethesda, MD: NHLBI; 2011. [http://www.nhlbi.nih.gov/about/factpdf.htm webcite]
• [12]Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, Reaman GH, Carroll WL: Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children’s oncology group. J Clin Oncol 2005, 2012(30):1663-1669.
• [13]Kessler RC, Demler RG, Olfson FM, Pincus HA, Walters EE, Wang P, Wells KB, Zaslavsky AM: Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005, 352:2515-2523.
• [14]Hyman SH: The diagnosis of mental disorders: the problem of reification. Ann Rev Clin Psychol 2010, 6:155-179.
• [15]Insel T, Cuthbert B, Garvey M, Heinssen R, Kozak M, Pine DS, Quinn K, Sanislow C, Steinberg J, Wang P: Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiat 2010, 167:748-751.
• [16]Clark LA, Watson D, Reynolds S: Diagnosis and classification of psychopathology: challenges to the current system and future directions. Ann Rev Psychol 1995, 46:121-153.
• [17]Van Praag HM: Nosologomania: a disorder of psychiatry. World J Biol Psychiatry 2000, 1:151-158.
• [18]Kendell R, Jablensky A: Distinguishing between the validity and utility of psychiatric diagnoses. Am J Psychiatry 2003, 160:4-12.
• [19]Hyman SH: Can neuroscience be integrated into the DSM-V? Nature Rev Neurosc 2007, 8:725-732.
• [20]Sanislow CA, Pine DS, Quinn KJ, Garvey MA, Heinssen RK, Wang PS, Cuthbert BN: Developing constructs for psychopathology research: Research Domain Criteria. J Abn Psychol 2010, 119:631-639.
• [21]Wong EHF, Yocca F, Smith MA, Lee C-M: Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters’ perspective. Int J Neuropsychopharm 2010, 13:1269-1284.
• [22]Miller G: Is pharma running out of brainy ideas? Science 2010, 329:481-482.
• [23]Schizophrenia AA: The drug deadlock. Nature 2010, 468:158-159.
• [24]Mirnezami R, Nicholson J, Darzi A: Preparing for precision medicine. NEJM 2012, 366:489-491.
• [25]Food and Drug Administration: FDA approves Kalydeco to treat rare form of cystic fibrosis. Silver Spring, MD: FDA; 2012. [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289633.htm webcite]
• [26]National Academy of Sciences: Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: National Academies Press; 2011.
• [27]National Institute of Mental Health: The National Institute of Mental Health Strategic Plan. Bethesda, MD: National Institute of Mental Health; 2008. [http://www.nimh.nih.gov/about/strategic-planning-reports/index.shtml webcite]
• [28]Davis M: Neural systems involved in fear and anxiety measured with fear-potentiated startle. Am Psychologist 2006, 61:741-756.
• [29]Treadway MT, Zald DH: Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosc Biobeh Rev 2011, 35:537-555.
• [30]Wager TD, Smith EE: Neuroimaging studies of working memory: a meta-analysis. Cogn Affect Behav Neurosci 2003, 3:255-274.
• [31]MacCorquodale K, Meehl PE: On a distinction between hypothetical constructs and intervening variables. Psychol Rev 1948, 55:95-107.
• [32]Krueger RF: The structure of common mental disorders. Arch Gen Psychiat 1999, 56:921-926.
• [33]Hudziak JJ, Achenbach TM, Althoff RR, Pine DS: A dimensional approach to developmental psychopathology. Int J Methods Psychiat Res 2007, 16:S16-S23.
• [34]Gold JM, Barch DM, Carter CS, Dakin S, Luck SJ, MacDonald AW III, Ragland JD, Ranganath C, Kovacs I, Silverstein SM, Strauss M, Strauss M: Clinical, functional, and intertask correlations of measures developed by the Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia Consortium. Schizophr Bull 2012, 38:144-152.
• [35]Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003, 289:2560-2571.